Pharmacovigilance et teratovigilance 2008 [Pharmacovigilance and teratovigilance 2008]


Autoria(s): Livio F.; Ivanyuk A.; Biollaz J.
Data(s)

2009

Resumo

Various signals and alerts of pharmacovigilance were issued in 2008. Frequent neuropsychiatric adverse events are reported with varenicline and rimonabant and the marketing authorization of the latter has been suspended. Ezetimibe/simvastatin combination is suspected of causing cancer while it's clinical utility remains to be proved. Neuroleptics, typical and atypical, are associated with an increased risk of death in elderly with dementia. Safety is a concern with various biological drugs. Rituximab, natalizumab and efalizumab are involved in rare cases of progressive multifocal leukoencephalopathy with fatal issue. Screening of HLA-B*5701, a good predictor of hypersensitivity reaction to abacavir, is recommended prior to starting therapy. Mycophenolate turns out to be a human teratogen.

Identificador

http://serval.unil.ch/?id=serval:BIB_A05E5C7AEF23

isbn:1660-9379

pmid:19238932

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 5, no. 186, pp. 130-134

Palavras-Chave #Abnormalities, Drug-Induced; Drug Therapy; Humans; Product Surveillance, Postmarketing
Tipo

info:eu-repo/semantics/article

article